Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate HIV-HBV infected individuals who have evidence of HBV replication in
the blood after taking 48 weeks of more of the HBV active medication tenofovir in combination
with emtricitabine or lamivudine. Eligible participants will be randomized to receive 24
weeks of entecavir (ETV) 1 mg versus continued standard of care antiretroviral therapy. After
24 weeks, individuals on entecavir or who remain HBV viremic on standard of care will receive
ETV o for an additional 24 weeks. The hypothesis is that intensification with entecavir will
reduce HBV DNA at 24 weeks more than continued antiretroviral therapy without entecavir.